20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Climb Bio Inc (CLYM) operates in the BIOTECHNOLOGY industry and is headquartered in Wellesley Hills, United States with about 28 employees. Its market capitalization is roughly $807 million. In the fiscal year ended 2025-12-31, CLYM reported $0M in revenue and ($60M) in net income.
Climb Bio, Inc., a clinical-stage biotechnology company, focuses on developing therapies to address unmet needs for patients living with immune-mediated diseases. The company's lead product candidate is the budoprutug, an anti-CD19 monoclonal antibody for the treatment of B-cell mediated diseases.
Interactive charts & full statements →
| Income statement | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M | $0M | $0M | $0M | — |
| Gross Profit | — | $0M | — | — | — | — | — | — |
| Gross Margin % | — | — | — | — | — | — | — | — |
| Operating Income (EBIT) | ($65M) | ($68M) | ($82M) | ($40M) | ($45M) | ($36M) | ($21M) | ($7M) |
| Operating Margin % | — | — | — | — | — | — | — | — |
| Net Income | ($58M) | ($60M) | ($74M) | ($35M) | ($45M) | ($47M) | ($21M) | ($7M) |
| Net Margin % | — | — | — | — | — | — | — | — |
| EBITDA | ($59M) | ($60M) | ($30M) | ($35M) | ($45M) | ($47M) | ($12M) | ($5M) |
| Earnings Per Share (EPS) | $-0.83 | $-0.88 | $-1.53 | $-1.30 | $-1.72 | $-3.87 | $-1.77 | $-0.56 |
| Shares Outstanding (M) | 76M | 68M | 48M | 27M | 26M | 12M | 12M | 12M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M | $0M | $0M | $0M | $0M |
| Gross Profit | — | $0M | $0M | $0M | $0M | — | — | — |
| Gross Margin % | — | — | — | — | — | — | — | — |
| Operating Income (EBIT) | ($15M) | ($15M) | ($19M) | ($15M) | ($11M) | ($23M) | ($11M) | ($12M) |
| Operating Margin % | — | — | — | — | — | — | — | — |
| Net Income | ($13M) | ($14M) | ($18M) | ($13M) | ($9M) | ($21M) | ($8M) | ($9M) |
| Net Margin % | — | — | — | — | — | — | — | — |
| EBITDA | ($15M) | ($14M) | ($17M) | ($13M) | ($9M) | ($21M) | ($8M) | ($9M) |
| Earnings Per Share (EPS) | $-0.18 | $-0.20 | $-0.26 | $-0.19 | $-0.13 | $-0.31 | $-0.13 | $-0.13 |
| Shares Outstanding (M) | 76M | 68M | 67M | 68M | 68M | 67M | 65M | 67M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Cash flow | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | ($53M) | ($54M) | ($16M) | ($21M) | ($37M) | ($36M) | ($14M) | ($5M) |
| Capital Expenditures (CapEx) | $0M | $0M | $0M | $0M | $0M | $0M | $0M | $0M |
| Free Cash Flow (FCF) | ($53M) | ($55M) | ($16M) | ($21M) | ($37M) | ($36M) | ($14M) | ($5M) |
| FCF Margin % | — | — | — | — | — | — | — | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly cash flow | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | ($11M) | ($14M) | ($16M) | ($12M) | ($11M) | ($15M) | ($6M) | ($8M) |
| Capital Expenditures (CapEx) | $0M | $0M | $0M | $0M | $0M | $0M | $0M | $0M |
| Free Cash Flow (FCF) | ($11M) | ($14M) | ($16M) | ($12M) | ($11M) | ($15M) | ($6M) | ($8M) |
| FCF Margin % | — | — | — | — | — | — | — | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $246M | $168M | $217M | $110M | $135M | $173M | $25M | $21M |
| Cash & Cash Equivalents | $44M | $36M | $87M | $93M | $44M | $47M | $20M | $21M |
| Total Liabilities | $7M | $7M | $5M | $3M | $6M | $6M | $3M | $1M |
| Total Debt (Short + Long-Term) | $1M | $0M | $0M | $0M | $0M | $0M | $0M | $0M |
| Total Shareholders' Equity | $240M | $160M | $212M | $108M | $129M | $167M | $22M | $21M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive CLYM viewer.
About TickerBase · Data methodology & sources · Privacy · Terms